Meta-Analysis of the Clinical Value of Danshen Injection and Huangqi Injection in Liver Cirrhosis

Table 1

Characteristics of the randomized controlled trials included in this study.

Author (reference)	Published year	Cases T/C	Age (years); Range, mean	Sex; Male/female	History (years); Range, mean
Shen et al. [5]	1999	39/35	T: 39–72, 55.3; C: 40–71, 56.5	T: 26/13; C: 23/12	2–13, 5.7
Chen et al. [6]	2000	80/40	NR	NR	NR
Cai et al. [7]	2001	44/40	T: 8–51, 29; C: 12–50, 31	T: 35/9; C: 32/8	T: 0.8–11, 5.9; C: 0.7–11, 5.8
Zhou [8]	2002	60/60	T: 28–70, 49; C: 26–68, 47	T: 40/20; C: 45/15	NR
Liu et al. [9]	2002	56/44	35–67	78/2	3–25
Chen et al. [10]	2003	43/42	36–71, 54.72	NR	NR
Cai [11]	2004	66/122	T: 54.6; C: 58.7	T: 59/7; C: 107/15	NR
Wu et al. [12]	2006	37/31	35–65	51/17	>2
Yi and Li [13]	2007	45/43	T: 20–55, 37; C: 18–51, 33	T: 25/20; C: 25/18	T: 5–13; C: 5–10
Pen and Wang [14]	2010	52/44	T: 28–69, 36.8; C: 24–67, 35.6	T: 38/14; C: 28/16	NR
Liu et al. [15]	2010	32/31	25–62, 39.7	T: 26/6; C: 23/8	NR

T: trials group, C: control group. NR: no report.